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ABSTRACT
Biological Activity of Garcinia kola seeds on Hepatitis C

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV).
According to the World Health Organization, hepatitis C infections affect
between 130-150 million people worldwide. It is a major cause of liver cirrhosis
and liver cancer, and approximately 500,000 people die from hepatitis C
infections or related complications each year. Although new treatments are 90%
effective at curing chronic hepatitis C infections, they cost tens of thousands of
dollars. Available treatments are incredibly cost prohibitive, especially
considering that the regions most affected by hepatitis C are Africa and central
and eastern Asia (“Hepatitis C”). This creates a need for the investigation of
more cost-effective HCV treatments in order to better serve the populations with
the highest prevalence of HCV infections.
The seeds of Garcinia kola, often referred to as bitter kola, have been used
as a folk medicine in Africa for hundreds of years. The seeds have cultural
significance to some Nigerian tribes, such as the Yoruba and Ibo tribes, and they
are frequently used in naming and marriage ceremonies (Adebisi 2004). In
traditional African medicinal practices, the seeds have been used as an
aphrodisiac, a stimulant, an antidiarrheal, a treatment for throat infections, and a
cough suppressant (Okoko 2009). However, there has been peer-reviewed
research revealing antihepatotoxic, antibacterial, and antioxidant activity present
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in the constituents of the Garcinia kola seed as well (Iwu 1987; Akinpelu;
Okoko).
In this study, the seeds of Garcinia kola were ground up and gravity
filtered with several solvents of differing polarities. The filtrates of these gravity
filtrations were then dried using rotary evaporation, fractionated using solid phase
extraction with silica cartridges or column chromatography, and dried again using
rotary evaporation. After being dried, the fractions were weighed and sent off for
a DCT bioassay to test for biological activity against hepatitis C.
The results of the bioassay revealed one Garcinia kola fraction with
significant biological activity against hepatitis C. The hexane crude extract of
Garcinia kola at a concentration of 10 μg/ml exhibited an inhibitory effect on the
HCV antigen and rRNA of 39.09% and 27.56%, respectively. In an attempt to
purify this crude extract, column chromatography with silica cartridges was
performed using a 10% gradient of hexane: ethyl acetate. These 10 new samples
were then dried using rotary evaporation. Nuclear magnetic resonance (NMR)
spectroscopy was then performed on the resulting fractions in an attempt to
characterize the structure of the molecule containing the hepatitis C biological
activity.
However, the fractionation by column chromatography with silica
cartridges of the crude hexane extract failed to completely separate the Garcinia
kola into its individual constituents. Therefore, there were multiple molecules
being displayed in each of the NMR spectra, making the identity of any individual
constituent of the hexane crude extract impossible to deduce. Due to this
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complication, the results of the NMR and the identity of the molecule containing
hepatitis C biological activity is incomplete. HPLC would be needed to
completely purify it. However, one possible candidate for the biological activity
against hepatitis C seen in the bioassay is kolaviron, a mixture of three chemically
similar biflavonoids: kolaflavanone, Garcinia biflavonone 1 (GB1), and Garcinia
biflavonone 2 (GB2).
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I. Introduction
i. Purpose
The purpose of this thesis is to explore the biological activity between
Garcinia kola and hepatitis C infections with the goal that the information
presented may eventually lead to drug discovery. This was accomplished through
extensive fractionation of the Garcinia kola seeds followed by DCT bioassay of
the resulting fractions to determine activity and NMR to determine structure.

ii. Background
Garcinia kola, more commonly known as bitter kola, is a flowering plant
that grows in the rainforests of central and western Africa. It is dicotelydenous
and grows in the humid lowland rainforests from Sierra Leone to Angola. It has a
slow rate of growth and a long gestation period before fruiting, which discourages
many farmers from choosing to cultivate it. Between July and October of each
season, the mature Garcinia kola tree produces reddish fruits, each of which
contains between 2 and 4 large seeds. The Garcinia kola seed has cultural
significance to some Nigerian tribes, such as the Yoruba and Ibo tribes, and it is
frequently used in naming and marriage ceremonies (Adebisi 2004).
In addition to its cultural uses, Garcinia kola has been heralded for its
supposed various medicinal qualities. For its traditional medical uses, the seed is
believed to be an aphrodisiac, a stimulant, and a cough suppressant. It is also used
for its alleged effects as a treatment for diarrhea, throat infections, and bronchitis
(Okoko 2009). The efficacy of these traditional uses has been largely unexplored;
however, Garcinia kola has a notable presence in research studies for its
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antihepatotoxic (Iwu 1987), antibacterial (Akinpelu), and antioxidant (Okoko
2009) properties.
Due to the nature of this thesis, the published antihepatotoxic properties of
Garcinia kola are of particular interest. There appear to be three known principal
biflavonoid constituents in Garcinia kola seeds that are believed to be responsible
for its antihepatotoxicity: kolaflavanone, Garcinia biflavonone 1 (GB1), and
Garcinia biflavonone 2 (GB2) (Akintonwa and Essein 1990). These three
molecules are very chemically similar, and the mixture of the three is collectively
referred to as kolaviron. In one study, pretreatment of either kolaviron, GB1, or
GB2 had significant positive effects on the survival rates of rats who were
administered doses of four known hepatotoxins: carbon tetrachloride,
galactosamine, α-amanitin, and phalloidin (Iwu 1987). Another study showed
that kolaviron was also had antihepatotoxic effects on the hepatotoxin
paracetamol (Akintonwa and Essein 1990).

Figure 1: Structure of kolaviron. For Garcinia biflavonone 1, R1 is OH and R2 is H. For Garcinia
biflavonone 2, R1 is OH and R2 is OH. For kolaflavonone, R1 is OCH3 and R2 is OH.

In one study completed by Maurice M. Iwu in 1987, kolaviron extracted
from the Garcinia kola seed had antihepatotoxic effects on four separate
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hepatotoxins. Carbon tetrachloride, galactosamine, α-amanitin, and phalloidin all
have different modes of action for their hepatotoxicity and all affect different
parts of the cell. Carbon tetrachloride is associated with damage to the rough
endoplasmic reticulum, phalloidin harms the plasma membrane of liver cells, αamanitin inhibits eukaryotic RNA-polymerase B, and galactosamine causes
necrosis of the liver and severely elevates the levels of three liver enzymes:
glutamic oxaloacetic transaminase (GOP), glutamic pyruvic transaminase (GPT),
and glutamate dehydrogenase (GLDH). This elevation can serve as a measure of
the damage done to the liver by hepatotoxins. Kolaviron was able to significantly
lower the concentrations of these liver enzymes in rats poisoned with carbon
tetrachloride and galactosamine. The protection of kolaviron against
galactosamine poisoning is particularly important, because the hepatotoxicity
caused by galactosamine resembles the lesions that are caused by viral hepatitis
(Akintonwa and Essein 1990).
When the kolaviron, GB1, or GB2 was administered via intraperitoneal
injection, they were not significantly more effective than the control saline
solution at reducing damage from hepatotoxins in mice. This suggests that the
activity of kolaviron on hepatotoxins comes from a byproduct of the metabolism
of kolaviron in the liver, rather than from the direct inactivation of the hepatotoxin
by kolaviron itself (Iwu 1987).
Kolaviron was also found to be effective at protecting against another
hepatotoxin called paracetamol. Paracetamol, also referred to as acetaminophen,
poisons the liver by depleting intracellular glutathione. A key function of
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glutathione is reducing the oxidizing agent N-acetyl-p-benzoquinoneimine
(NAPQI), a metabolite formed by cytochrome P-450 mixed function oxidase. If
there is not a sufficient amount of glutathione to detoxify NAPQI, the NAPQI will
covalently bond to cell macromolecules, resulting in cell death. When rats were
pretreated with kolaviron prior to paracetamol poisoning, the rate of lethality was
very significantly reduced. It has therefore been suggested that kolaviron, or one
of the byproducts of the metabolism of kolaviron, may act as an inhibitor to
cytochrome P-450 mixed function oxidase, or it may reduce the NAPQI itself
(Akintonwa and Essein 1990).
Hepatitis C is a liver disease that chronically affects between 130-150
million people globally. It is caused by the acquisition of the hepatitis C virus,
which is a blood borne, positive strand, enveloped RNA virus usually spread by
unsafe injection practices. There are six different genotypes of the virus, and
treatment is dependent on which genotype the patient has (“Hepatitis C”). The
infection can be either acute or chronic. The acute infection can be asymptomatic
and between 15-30% of people who are infected are able to clear the virus without
any treatment within six months (“Viral Hepatitis- Hepatitis C Information”).
However, the remainder of those infected will proceed to develop the more
serious, chronic hepatitis C infection.
Of those who develop the chronic hepatitis C infection, 15-30% will
develop cirrhosis within twenty years and a significant number will develop liver
cancer. Annually, between 350,000- 500,00 people die from hepatitis C related
liver diseases, and no vaccine is available. Antiviral treatments, which can help
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prevent cirrhosis and liver cancer caused by hepatitis C, are successful in between
50-90% of those treated, but the treatment is not widely available and access to
diagnosis is low. Hepatitis C is most concentrated in Africa and Asia, though it is
present worldwide (“Hepatitis C” 2015).

Figure 4: Chronic hepatitis C infection global prevalence (reprinted from Holmburg
2012)

In recent years, there has been great progress in the treatment of hepatitis
C. Before 2011, there were only two FDA approved drugs that treated hepatitis
C. These medications were generally prescribed together, and less than one half of
patients receiving this treatment achieved a sustained virologic response
(McCarthy 2010). The first drug in this regimen was called pegylated interferon.
Pegylated interferon is an injection that contains a protein, IFN- α/β, that activates
natural killer cells so that they have a greater cytotoxic potential to fight hepatitis
C infections (Chung 2008). The second drug in the regimen is ribavirin, which
acts by enhancing the response of hepatic genes to IFN- α/β (Chung 2008). Since
new drugs have come to market, however, pegylated interferon and ribavirin are
11
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being phased out in favor of more effective drugs that can treat a wider variety of
patients (“Advances in Medications to Treat Hepatitis C” 2015).
One of the major advancements in hepatitis C treatment came in 2013
when a once daily pill called Sofosbuvir (brand name Sovaldi) made it to market.
Sofosbuvir is a NS5B polymerase inhibitor that treats HCV genotypes one, two,
three, and four. The NS5B protein is essential for HCV viral replication, making it
a useful target. Its structure contains a uridine analog that, when activated by
triphosphorylation by hepatic enzymes in the liver, simulates the uridine
nucleotide therefore competitively blocking the NS5B polymerase at the binding
site for uridine. This inhibits the RNA synthesis of the hepatitis C virus by
causing chain termination (Bhatia 2014). Sofosbuvir was also the first hepatitis C
drug that could treat patients with hepatitis C and HIV co-infections.
Unfortunately, Sovaldi costs approximately $1000 per pill, making the total cost
for a twelve-week regimen about $84,000 (“Advances in Medications to Treat
Hepatitis C” 2015).
Another advancement in hepatitis C treatment came in 2014 with another
once daily pill called Harvoni. Harvoni combines sofosbuvir with another drug
called Ledipasvir (“Advances in Medications to Treat Hepatitis C”). Ledipasvir is
an inhibitor of the NS5A protein produced by the hepatitis C virus (Lim 2014).
Its exact mechanism of action is unclear, though evidence supports that ledipasvir
directly binds to the hepatitis C viral protein NS5A (Kwon 2015). Harvoni only
treats hepatitis C genotype one. Like Sovaldi, it is expensive; each pill costs
$1125. It is prescribed on an 8 or 12-week regimen, making the total cost of
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treatment with Harvoni between $63,000 and $94,500. Fortunately, it is very
effective; Harvoni cured 94% of people of their hepatitis C infections after 12
weeks of treatment in clinical trials (“Advances in Medications to Treat Hepatitis
C” 2015).

Figure 5: Structure of Ledipasvir

Figure 6: Structure of Sofosbuvir

Other effective treatments, such as Viekira Pak, Technivie, and Daklinza
have also come to market since 2014. Viekira Pak is a combination of 4 drugs:
ombitasvir, paritaprevir, ritonavir, and dasabuvir. It blocks the HCV NS3/4A
protease complex and the HCV NS5A protein ("Viekira Pak,
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Ombitasvir/paritaprevir/ritonavir plus Dasabuvir." 2016). Ritonavir has no
activity itself against HCV, but rather it acts as a pharmokinetic enhancer. It
helps to increase the concentration of one of the other drugs, paritaprevir.
Ombitasvir acts as a NS5A protein inhibitor, and paritaprevir acts as an inhibitor
to the NS3/4A protease. Lastly, Dasabuvir inhibits the NS5B polymerase.
(Ombitasvir, paritaprevir/ritonavir plus dasabuvir (Viekira Pak) 2015).
Technivie is made of ombitasvir, paritaprevir, and ritonavir. Viekira Pak,
Daklinza, and Technivie have similar shortcomings as Sovaldi and Harvoni; they
only treat certain genotypes of hepatitis C and they are cost prohibitive. Viekira
Pak costs $83,320 for a twelve-week regimen. When used in conjunction with
ribavirin, which it often is, the cost increases to $85,820. In addition, it cannot
treat patients with advanced cirrhosis. Technivie only treats genotype four,
cannot treat patients with cirrhosis, and costs $76,653 for a 12 week regimen (plus
$2500 for ribavirin which is usually prescribed with it). One of the newest drugs,
daclatasvir (brand name Daklinza), is a direct acting antiviral that treats genotype
three (“Advances in Medications to Treat Hepatitis C” 2015). Like ledipasvir, it
is an antiviral that acts directly on the NS5A HCV protein, though it acts on a
different site on the protein than ledipasvir (Lim 2014). It costs $63,000 for a
twelve-week regimen, but it is prescribed with Sovaldi, which costs $84,000 for a
twelve-week regimen (“Advances in Medications to Treat Hepatitis C” 2015).
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Figure 7: Daklinza structure

Figure 8: Ombitasvir structure

Figure 9: Paritaprevir structure
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Figure 10: Ritonavir structure

Figure 11: Dasabuvir structure

Though effective, these treatments present two very serious problems: cost
and availability. The regions of the world most affected by hepatitis C are in
Africa as well as central and eastern Asia. Despite the fact that nearly 90% of
patients could be cured of their HCV infections if given the correct treatments,
there are still about 500,000 people who die every year due to HCV related
conditions (“Hepatitis C” 2015). Therefore, a need exists to explore more cost
effective treatments so that the populations most in need of hepatitis C treatments
can have affordable access to them. Fortunately, Garcinia kola is widely
cultivated in Africa, where the highest prevalence of HCV infections are
estimated to be, and it is administered orally for its antihepatotoxic effects
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(Akintonwa and Essein 1990). In addition, the seeds are edible and they are
considered “megadoses” of kolaviron (Iwu 1987).
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II. Experimental

Garcinia kola fractions were prepared according to two separate procedures.
Fractions from both procedures were sent off for DCT bioassay.

i. First Procedure
To begin, two 750 g samples of Garcinia kola were blended in a
commercial blender to a sand-like consistency. One sample, to be referred to as
the “dry sample,” was left under a fume hood for one week. The other sample,
the “wet sample,” was not left under the hood. Both samples were gravity filtered
with 500 mL of hexane, chloroform, ethanol, and water, in that order. Each
filtrate was collected and saved, then dried down using rotary evaporation until of
all the solvent had evaporated. The fractions were then photographed and
weighed.

Figure 12: Fractions prior to rotary evaporation. From left to right: ethanol fraction, hexane
fraction, chloroform fraction, water fraction

Following being photographed and weighed, each crude extract underwent
solid phase extraction using silica cartridges. To accomplish this, 25 mg of each
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extract was collected, placed in a silica cartridge, and vacuum filtered with the
following compositions of solvents in order:
100% Hexane
50:50 Hexane: Ethyl Acetate
100% Ethyl Acetate
50:50 Ethyl Acetate: Methanol
100% Methanol
100% Water
However, following the solid phase extraction of the hexane crude extract,
it was observed that the majority of the extract was still present in the silica
cartridge after all of the solvents had passed. It was decided that a more complete
gradient of polarity could help pass a greater amount of the crude extract through
the silica cartridge. This led to a modification of the solvent compositions in an
effort to maximize the yield of extracted molecules in the filtrate. The new
procedure consisted of the following solvent compositions:
100% Hexane
75:25 Hexane: Ethyl Acetate
50:50 Hexane: Ethyl Acetate
25:75 Hexane: Ethyl Acetate
100% Ethyl Acetate
75:25 Ethyl Acetate: Methanol
50:50 Ethyl Acetate: Methanol
25: 75 Ethyl Acetate: Methanol
100% Methanol
50:50 Methanol: Water
100% Water
This new procedure did appear to increase the mass of the crude extract
that passed through the silica cartridge into the filtrates during solid phase
extraction, so it was used for the subsequent solid phase extractions of the
chloroform, ethanol, and water crude extracts. Each of the filtrates were dried
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down using rotary evaporation until the solvent had evaporated. For several of
these samples, 2 mg was weighed and sent off for DCT bioassay.

ii. Second Procedure
A 2.26 kg batch of Garcinia kola seeds arrived and some slight
modifications were made to the procedure. The Garcinia kola seeds were placed
in a grinder rather than a blender, and they were ground to a powder like
consistency. The solvents used in gravity filtration for the crude extraction were
also revised. In chronological order, the solvents used in the second procedure
consisted of hexane, ethyl acetate, ethanol, and a 50:50 mixture of ethanol and
water. Rather than being immediately gravity filtered after blending, the Garcinia
kola seeds were covered in each respective solvent, sonicated in a hot water bath
at 42 oC for 30 minutes, vacuum filtered, sonicated at 42 oC for 30 minutes again,
and finally vacuum filtered again. This procedure was repeated for each of the
four solvents.

a

Figure 14:(left to right) Ethanol precipitate, ethyl acetate partition, ethanol
partition
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The ethanol fraction required slightly different treatment because a
precipitate (visible in figure 6) was present. To collect the precipitate, the liquid
portion of the fraction was decanted, leaving the precipitate with minimal solvent.
Rotary evaporation was then performed on the precipitate portion to remove the
remaining solvent. The liquid portion of the ethanol sample was partitioned with
ethyl acetate, creating two distinct layers that were then separated using a pipette.

Figure 15: Ethanol fraction after partitioning

Each extract was photographed and weighed. Finally, 2 mg of each of the
extracts was collected and sent for DCT bioassay. Once the results of the bioassay
were obtained, it was noted that the crude hexane extract had the most promising
biological activity against hepatitis C. Due to this observation, the crude hexane
extract was chosen to undergo further study. Column chromatography was
performed on the crude hexane extract using a 10% gradient of hexane: ethyl
acetate in an attempt to purify it. The fractions resulting from the column
chromatography were then collected, weighed, and imaged using NMR
spectroscopy.
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Figure 16: Hexane crude extract during column chromatography with a 10% gradient of hexane:
ethyl acetate

Figure 17: Garcinia kola fractionation scheme
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III. Results
The crude extract with the most promising biological activity against HCV
infections of the samples that were tested was the hexane crude extract produced
from the second procedure discussed in the Experimental section. Due to this
activity, the hexane extract was further fractionated using column
chromatography, then the fractions were imaged using NMR spectroscopy.
Table 1: Masses of first procedure Garcinia kola crude
extracts
Wet
Dry
Crude
Sample
Sample
Extract
Mass
Mass
Hexane
0.2531 g
0.2802 g
Chloroform
0.8989 g
1.1965 g
Ethanol
7.5858 g
3.0464 g
Water
2.9499 g
0.9314 g
Table 2: Mass of second procedure Garcinia kola crude
extracts
Crude Extract
Hexane
Ethyl Acetate
Ethanol (Precipitate)
Ethanol (Ethanol Partition)
Ethanol (Ethyl Acetate Partition)

Mass
3.9992 g
17.57 g
5.8231 g
12.8398 g
10.368 g
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Table 3: Biological activity of Garcinia kola fractions on hepatitis C
% Inhibition

Fraction
Hexane crude
extract
Ethyl acetate
crude extract
Ethyl Acetate
Partition of
Ethanol Fraction
Precipitate of
Ethanol Fraction
Ethanol fraction
Water crude
extract, filtered
through silica
with 75:25 ratio
of Hexane: Ethyl
acetate
Water crude
extract, filtered
through silica
with 50:50 ratio
of Hexane: Ethyl
acetate
Water crude
extract, filtered
through silica
with 25:75 ratio
of Hexane: Ethyl
acetate
Ethanol crude
extract, filtered
through silica
with 75:25 ratio
of Hexane: Ethyl
acetate
Ethanol crude
extract, filtered
through silica
with 50:50 ratio
of Hexane: Ethyl
acetate

DC
t
HC
V
0.7
2
0.6
5
0.2
2
0.1
3
0.4
4

DCt
rRN
A

HCV

0.47

39.09

0.28

-56.25

rRN
A
27.5
6
21.4
9

0.13

-16.35

9.52

0.41

-9.34

24.5
0

0.06

-35.45

3.84

-36.71

21.4
9

0.4
5

0.28

0.3
5

0.82

-27.29

75.6
2

0.2
7

0.03

-20.72

2.21

0.4
4

0.24

-35.14

17.9
0

0.4
6

0.28

-37.66

21.6
3
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Figure 18: NMR spectrum of 100% hexane fraction of Garcinia kola hexane crude extract
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Figure 19: NMR spectrum of 9:1 hexane: ethyl acetate fraction of Garcinia kola hexane crude
extract
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Figure 20: NMR spectrum of 8:2 hexane: ethyl acetate fraction of Garcinia kola hexane crude
extract
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Figure 21: NMR spectrum of 7:3 hexane: ethyl acetate fraction of Garcinia kola hexane crude
extract
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Figure 22: NMR spectrum of 6:4 hexane: ethyl acetate fraction of Garcinia kola hexane crude
extract
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IV. Discussion
Hexane was the only crude extract that showed biological activity against
hepatitis C. In the DCT bioassay, the hexane crude extract at a concentration of
10 μg/ml exhibited an inhibitory effect on the HCV antigen and rRNA of 39.09%
and 27.56%, respectively. Having identified the fraction with the most biological
activity against hepatitis C, the next objective was to identify the specific
compound in the crude extract that was responsible for the activity. However,
attempting to isolate this molecule resulted in many obstacles. Column
chromatography was used in an attempt to separate the hexane crude extract into
its individual constituents. This eluted ten new fractions, however it was clear
from the NMR data that the fractions were not completely pure. In analyzing the
NMR spectra, each of the fractions appeared to consist of multiple molecules.
Therefore, it was impossible to hypothesize a single structure from the spectra
because multiple compounds were being measured. In addition, there appeared to
be “bleed over” in the spectra, meaning that the spectra that were adjacent in the
hexane: ethyl acetate gradient appeared to have similar peaks in the NMR spectra.
This is most likely because some of the molecules that were soluble at one given
solvent ratio on the gradient were also somewhat soluble at the adjacent solvent
ratios on the gradient. Therefore, the same molecules were able to appear in
multiple NMR spectra, which resulted in striking similarities between some of the
spectra.
While the identity of the unknown molecule(s) contributing to the hepatitis
C biological activity cannot be ascertained with certainty from the NMR spectra
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or bioassay, there is evidence to support that the cause of the hepatitis C activity
could be kolaviron.
The evidence supporting kolaviron as the source of the biological activity
is largely coincidental. There exists a published procedure to extract kolaviron
from Garcinia kola. In the procedure, Garcinia kola seeds are peeled, sliced,
pulverized, and dried at 40 oC. Following this drying, the Garcinia kola seed
powder is extracted with petroleum ether in a soxhlet extractor for 24 hours.
Having been defatted from the soxhlet extraction, the remains of the crushed
seeds are then repacked and extracted with acetone. This marc is then
concentrated and diluted to two times its volume using water and finally extracted
with ethyl acetate (Iwu 1985). The procedure that was carried out in this
experiment differed from the accepted procedure for the isolation of kolaviron.
Petroleum ether, the solvent used to defat the Garcinia kola seeds in the published
procedure, has the same polarity index (0.1) as hexane. Because a soxhlet
extraction is necessary to defat the kolaviron before it is extracted, it seems
reasonable that the kolaviron may be in some way associated with the lipids
present in the Garcinia kola seed. Therefore, a possible explanation for the
presence of biological activity in the hexane fraction is that the kolaviron is
associated with lipids in the Garcinia kola seed, which causes it to be moderately
soluble when extracted with hexane.
Another reason that kolaviron is a candidate for the biological activity
against hepatitis C is its known antihepatotoxic effects across multiple
hepatotoxins. Orally administered kolaviron has been shown to combat multiple
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hepatotoxins that have different modes of action, including paracetamol,
galactosamine, carbon tetrachloride, phalloidin, and α-amanitin. Notably,
galactosamine poisoning mimics some features of hepatitis, and kolaviron has
significant protective effects against galactosamine injury. However, without a
bioassay of isolated kolaviron, it is impossible to identify the constituent
containing hepatitis C activity with certainty.
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